Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
9.08
-0.34 (-3.61%)
At close: May 15, 2026, 4:00 PM EDT
9.05
-0.03 (-0.33%)
After-hours: May 15, 2026, 5:57 PM EDT
Arvinas Employees
Arvinas had 246 employees as of December 31, 2025. The number of employees decreased by 184 or -42.79% compared to the previous year.
Employees
246
Change (1Y)
-184
Growth (1Y)
-42.79%
Revenue / Employee
$363,415
Profits / Employee
-$899,593
Market Cap
585.85M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 246 | -184 | -42.79% |
| Dec 31, 2024 | 430 | -15 | -3.37% |
| Dec 31, 2023 | 445 | 30 | 7.23% |
| Dec 31, 2022 | 415 | 135 | 48.21% |
| Dec 31, 2021 | 280 | 101 | 56.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 674 |
| Gyre Therapeutics | 625 |
| CorMedix | 191 |
| Rigel Pharmaceuticals | 174 |
| Cabaletta Bio | 156 |
| Kyverna Therapeutics | 130 |
| Adlai Nortye | 109 |
| Aclaris Therapeutics | 73 |
ARVN News
- 3 days ago - Arvinas price target raised to $16 from $14 at BofA - TheFly
- 3 days ago - Arvinas price target raised to $18 from $16 at BTIG - TheFly
- 3 days ago - Arvinas price target raised to $20 from $18 at Barclays - TheFly
- 4 days ago - H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’ - TheFly
- 4 days ago - Arvinas, Pfizer enter license pact with Rigel Pharmaceuticals for Veppanu - TheFly
- 4 days ago - Rigel Pharmaceuticals enters license agreement with Arvinas, Pfizer - TheFly
- 4 days ago - Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug - Reuters
- 4 days ago - Arvinas Earnings Call Transcript: Q1 2026 - Transcripts